| 3.09 Data as of 11:50am ET |  -0.038 / -1.21%Today’s Change | 2.33 Today|||52-Week Range 4.60 | +18.02% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $163.2M |
Company Description
SIGA Technologies, Inc. is a pharmaceutical company. It is engaged in the development and commercialization of therapeutic solutions for some of the lethal disease causing pathogens - smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. The company's business is to discover, develop, manufacture and successfully commercialize drugs to prevent and treat these high priority threats. Its product, ST-246, is an orally administered antiviral drug that targets orthopoxviruses. The company's focuses to disarm dreaded viral diseases and create robust, modern biodefense countermeasures. SIGA Technologies was founded on December 28, 1995 and is headquartered in New York, NY.
Employees
Shareholders
| Individual stakeholders | 33.31% |
| Other institutional | 22.16% |
| Mutual fund holders | 11.48% |
Top Executives
| Eric A. Rose, MD | Chairman & Chief Executive Officer |
| Daniel J. Luckshire, MBA, CPA | Chief Financial Officer, Secretary & Executive VP |
| Dennis E. Hruby, PhD | Chief Scientific Officer |
| William J. Haynes, II | Executive Vice President & General Counsel |
.
